Trial Profile

Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care for Newly Diagnosed Adult Glioblastoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dubodencel (Primary)
Indications Glioblastoma
Focus Therapeutic Use
Sponsors Diakonos Oncology

Most Recent Events

17 Feb 2026 According to Diakonos Oncology media release, a scheduled safety review DSMB review has been completed for this study approximately after 6 months after the first patient was treated. No safety concerns were observed and the study can be continued as planned.
12 Aug 2025 According to Diakonos Oncology media release, company recently completed the successful manufacturing of the first doses to support the initiation of the Phase 2 clinical trial of DOC1021.
30 Jul 2025 Planned number of patients changed from 135 to 180.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com